Clinical trials: Antithrombotic Therapy
Bleeding
Bleeding Events After Triple Antithrombotic Therapy Initiation.
The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold…
- Trial name
- HEMOTRI (NCT03203980)
- Testing
- Triple antithrombotic therapy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Cerebrovascular Disease
Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease
To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.
- Trial name
- NCT03471169
- Testing
- Desirable TEG, Undesirable TEG
- Where
- China
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Terminal Cancer
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
Despite the fact that antithrombotic therapy (ATT) has little or even negative effects on the well-being of cancer patients during their last year of life, stopping ATT is rare in clinical practice.
- Trial name
- SERENITY (NCT05706740)
- Testing
- Physician survey on antithrombotic medication during end-of-life care in cancer patients
- Where
- 12 sites in Denmark, France and 6 more
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease
Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease
EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.
- Trial name
- NCT04994223
- Testing
- Rivaroxaban 10 MG Oral Tablet [Xarelto]
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Placental Vascular Pathologies, Venous Thromboembolism Diseases
Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women
The venous thromboembolism is one of the first causes of maternal mortality. Until 2003, only a few recommendations were available on the optimal use of antithrombotic therapy as a preventive measure against thromboembolism in…
- Trial name
- STRATHEGE (NCT00745212)
- Where
- France
- Volunteers
- 2,280 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Thrombosis, Blood Coagulation Disorder
Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)
Consenting patients with end-stage heart failure that are implanted with/candidates for implant of a short-term/durable mechanical circulatory support device (e.g.: percutaneous microaxial pumps (Impella), extracorporeal membrane…
- Conditions
- Thrombosis, Blood Coagulation Disorder, Platelet Thrombus, Platelet Dysfunction Due to Aspirin
- Trial name
- PASVAD (NCT03255928)
- Testing
- PAS assay, TGT
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Scientific Institute San Raffaele
Healthy Volunteers
A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
This study will investigate the safety and interaction of BMS-986177 in healthy volunteers, when administered with Aspirin and/or Clopidogrel
- Trial name
- NCT03698513
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Stroke, Ischemic
Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors
This study evaluated the feasibility and acceptability of using a SystemCHANGE intervention in older adult stroke survivors to improve medication adherence.
- Trial name
- NCT03211130
- Testing
- SystemCHANGE™, Attention-Control
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Missouri, Kansas City
Antithrombotic Agents Management
Management of Anticoagulant Therapy in Non-cardiac Surgery.
The perioperative treatment of patients receiving long-term anticoagulant therapy is challenging. This is attributed to the continuation of anticoagulants perioperatively, which is associated with an increased bleeding risk while…
- Trial name
- NCT04766606
- Where
- Greece
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- University of Ioannina
Atrial Fibrillation, Acute Coronary Syndrome
Antithrombotic Triple Therapy in Humans
Background:The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality.
- Trial name
- NCT01812200
- Testing
- Dabigatran, Ticagrelor, ASA, Rivaroxaban, Ticagrelor, ASA, Phenprocoumon, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Patent Foramen Ovale, Ischemic Stroke
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
- Conditions
- Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
- Trial name
- HALTI (NCT04475510)
- Testing
- Antiplatelet treatment discontinuation
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Josep Rodes-Cabau
Intracerebral Hemorrhage, Hemorrhagic Risk Conditions
Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is associated with high mortality and long-term disability, and effective treatment options remain limited.
- Conditions
- Intracerebral Hemorrhage, Hemorrhagic Risk Conditions, Bleeding Disorders
- Trial name
- MIMICK-TIPITCH (NCT07411079)
- Testing
- Ex vivo exposure to modified rtPA
- Where
- France
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited